Free Trial
LON:TRX

Tissue Regenix Group (TRX) Share Price, News & Analysis

Tissue Regenix Group logo
GBX 61.67
+1.79 (+2.99%)
(As of 11:29 AM ET)

About Tissue Regenix Group Stock (LON:TRX)

Key Stats

Today's Range
58
61.67
50-Day Range
51.60
66
52-Week Range
50
75
Volume
47,390 shs
Average Volume
79,539 shs
Market Capitalization
£43.93 million
P/E Ratio
N/A
Dividend Yield
4.12%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of bone graft substitutes and soft tissue in the United States and internationally. The company operates through dCELL, BioRinse, and GBM-V segments. It also provides dCELL technology, a soft tissue decellularisation process that removes DNA and other cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductivity to stimulate and regenerate native bone growth. In addition, the company offers DermaPure, a decellularised dermal allograft for reinforcement, repair, and replacement of damaged or inadequate integumental tissue and other homologous uses of human integument; and SurgiPure XD, a decellularised porcine dermal reconstructive tissue matrix for the repair of hernias and body wall defects. Further, it provides OrthoPure XT, a scaffold to replace the damaged tissue that will re-populate with the patient's own cells; ConCelltrate 100, a verified osteoinductive bone matrix; MatrixCellect 100, a demineralised bone matrix (DBM) for orthopaedic; Matrix IQ Dermis, a human-derived dermal graft, which is decellularised to remove cellular components and preserve the biological properties that promote revascularisation, repair, and augmentation of damaged tissue; and Matrix OI FlexIt, a thin pliable demineralised cortical allograft bone sheet. Additionally, the company offers DentalFix, a mineralized particulate allograft that offer osteoconductive properties of natural bone; Matrix OI 100 DBM for non-structural bone-grafting; Matrix OI Strips and Blocks, a stem cell containment human scaffold; AmnioWorks to optimise membrane defects; and sports medicine products. Tissue Regenix Group plc was incorporated in 2006 and is based in Garforth, the United Kingdom.

Receive TRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tissue Regenix Group and its competitors with MarketBeat's FREE daily newsletter.

TRX Stock News Headlines

Tissue Regenix Group Share Chat (TRX)
Watch this before it gets removed
If you missed it, my emergency election broadcast is now available - but will be removed soon
Tissue Regenix Group PLC (LSW.BE)
Tissue Regenix Group plc (TRX.L)
See More Headlines

TRX Stock Analysis - Frequently Asked Questions

Tissue Regenix Group's stock was trading at GBX 52 at the start of the year. Since then, TRX stock has increased by 18.6% and is now trading at GBX 61.67.
View the best growth stocks for 2024 here
.

Tissue Regenix Group plc (LON:TRX) released its earnings results on Wednesday, September, 2nd. The company reported ($0.16) earnings per share for the quarter. Tissue Regenix Group had a negative trailing twelve-month return on equity of 3.31% and a negative net margin of 3.46%.

Shares of TRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tissue Regenix Group investors own include Lloyds Banking Group (LLOY), Argos Therapeutics (ARGSQ), FuelCell Energy (FCEL), TransEnterix (TRXDW), Swedbank AB (publ) (SWDBY), Trevena (TRVN) and Barrick Gold (ABX).

Company Calendar

Last Earnings
9/02/2020
Today
11/04/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Precious Metals
CIK
N/A
Fax
N/A
Employees
120
Year Founded
N/A

Profitability

Net Income
£-1,100,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£31.80 million
Cash Flow
GBX 10.82 per share
Book Value
GBX 43 per share

Miscellaneous

Free Float
N/A
Market Cap
£43.93 million
Optionable
Not Optionable
Beta
1.61
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

This page (LON:TRX) was last updated on 11/4/2024 by MarketBeat.com Staff
From Our Partners